EUROPEAN JOURNAL OF PHARMACEUTICAL AND MEDICAL RESEARCH

PREVALENCE AND ROLE OF CBNAAT IN DIAGNOSIS OF TUBERCULAR MENINGITIS

Dilbag Singh[1*], Amritpal Kaur[1] and Naveen Pandhi[2]

[1]Junior Resident, Dept. of Pulmonary Medicine, GMC Amritsar, Punjab, India.
[2]Professor and Head, Dept. of Pulmonary Medicine, GMC Amritsar, Punjab, India.

*Corresponding Author: Dr. Dilbag Singh

Junior Resident, Dept. of Pulmonary Medicine, GMC Amritsar, Punjab, India.

ABSTRACT

Tuberculous meningitis (TBM) is the most severe form of tuberculosis. Microbiological confirmation is rare, and treatment is often delayed, increasing mortality and morbidity. Due to paucibacillary nature of CSF, it is difficult to demonstrate tubercle bacilli by the standard staining procedures which is the gold standard for diagnosis, thus leading to a large number of cases being undiagnosed or misdiagnosed. Meticulous examination of a smear from a large volume of cerebrospinal fluid (CSF) remains the most sensitive technique but is not practical in most laboratories. The Xpert MTB/RIF represents a significant advance in the early diagnosis of this devastating condition. So, this study was done with the aim to know the Prevalance and role of CBNAAT in the diagnosis of tubercular meningitis. Out of 50 patients included in the study, 4 were Definite TBM, 31 were probable TB, 12 were possible TBM and 3 were not TBM.Total 15 patients had M. TB detected in their CSF on CBNAAT, out of a total of 47 TBM patients.The sensitivity of CBNAAT in our study was 31%.

KEYWORDS: CBNAAT, GeneXpert, Tubercular meningitis, CSF.

INTRODUCTION

The first description of TBM dates back to 1836 when six cases of acute hydrocephalus in children characterized by 'an inflammation of the meninges, with the deposit of tubercular matter in the form of granulations, or cheesy matter' were described in the Lancet.1 Among various forms of extrapulmonary TB, tuberculous meningitis (TBM) is the most severe form and remains a major global health problem with the case fatality rate for untreated TBM reaching almost 100 %,2 even after more than 100 years. Early recognition of TB meningitis is of paramount importance because the clinical outcome depends greatly upon the stage at which the therapy is initiated,3 and delay in treatment often leads to permanent neurological damage. The diagnosis of TBM has been a continuous challenge. Definitive diagnosis requires demonstration of tubercle bacilli in CSF, which can be done either by smear microscopy or culture. Smear microscopy is inexpensive and rapid but insensitive (0–20 %) due to low microorganism densities in CSF, while culture techniques are unacceptably slow which makes it unsuitable as a routine technique for rapid confirmatory diagnosis.2,4 Thus, diagnosis of tubercular meningitis basically remains presumptive and is based on clinical symptoms, neurologic signs, CSF findings, CT scans, and response to anti-TB drugs.Cartridge Based Nucleic acid-based amplification test(CBNAAT) or GeneXpert has now emerged as potentially important tool for diagnosing TBM. The GeneXpert System (Cepheid) is a single use cartridge-based real-time PCR fully automated system that performs sample decontamination, sonication, automated nucleic acid amplification, and fluorescence-based quantitative PCR.5-7 The published Xpert MTB/RIF detection threshold is approximately 100 - 130 colony forming units (cfu)/ml of sample.5,6 . According to recent WHO guidelines, Xpert MTB/RIF should be used in preference to conventional microscopy and culture as the initial diagnostic test in testing cerebrospinal fluid specimens from patients presumed to have TB meningitis in order to reach quick diagnosis. If sufficient volume of material is available, concentration methods should be used to increase yield. So, the present study was undertaken to evaluate the role of CBNAAT in early detection of tubercular meningitis and to also detect rifampin resistance in this era of alarming rise of multi-drug resistant strains of mycobacterium.

MATERIALS AND METHODS

This prospective study was carried out in the Dept of Tuberculosis and Respiratory Diseases, Govt. Medical College, Amritsar after approval from the institution's ethical committee.All the patients being admitted in the wards from March 2019 to november 2019, with signs and symptoms suggestive of tubercular meningitis were included in the study after taking their or guardian's (in case of unconscious patients or children) informed consent.

Inclusion criteria
1. Patients having clinical features of meningitis with or without signs of meningeal irritation.
2. Patients with a subacute onset of symptoms(>5 days) or a positive contact history.
3. MRI brain findings suggestive of tubercular meningitis.
4. CSF showing features of pleocytosis, predominantly lymphocytosis, decreased glucose levels, high protein levels and an ADA >10 IU/L.
5. Presence of tuberculosis elsewhere(eg miliary tuberculosis or abdominal TB)

Exclusion criteria
1. Patients with features suggestive of pyogenic meningitis.
2. Patients refusing to give consent for th

Complete history including past or family history of tuberculosis was taken. Complete physical examination was done including level of consciousness, signs of meningeal irritation (neck stiffness, Kernig's sign, Brudzinski's sign), cranial nerve involvement, etc. Lumbar Puncture was done after ruling out papilloedema after taking consent and CSF was subjected to cytology, biochemistry, ADA, fungalstain, smear for AFB, culture and CBNAAT. Other investigations like TLC, DLC, ESR, blood culture, mantoux, HIV etc were done. Chest Xray and MRI were done in relevant cases. Then, the cases were divided into probable TBM, possible TBM and definitive TBM according to Diagnostic Criteria in the Uniform Tuberculous Meningitis Research Case Definition as given by Suzaan Marais et al as published in The Lancet.12 Xpert MTB/RIF results were not included in the case definition, because it was the test under evaluation. Definite TBM was defined as a clinical syndrome consistent with TBM, with acid-fast bacilli seen on CSF smear or M. tuberculosis isolated in CSF MGIT culture. Patients in the "probable TBM" group had a diagnostic score of 10 or more without cerebral imaging (MRI or CT scan) or 12 or more with cerebral imaging, with at least 2 points from CSF or cerebral imaging criteria. Patients in the "possible TBM" group had a diagnostic score of between 6 and 9 if cerebral imaging was not performed or between 6 and 11 if cerebral imaging was performed.All patients who had a score below 5 were classified as not having TBM.

RESULTS
50 patients were included in the study who had features suggestive of tubercular meningitis. Out of these, 33 were male and 17 were female. 20 patients were of age group 0-15 years, 12 patients were in age group 16-30 years and 18 patients were aged > 30 years.

According to the universal case definition, the patients were divided into probable, possible and definitive TBM. Out of 50 patients included in the study, 4 were Definite TBM, 31 were probable TB, 12 were possible TBM and 3 were not TBM.

Table 1- Age distribution of patients.

Age group	No. of patients	Percentage
0-15 years	20	40%
16-30 years	12	24%
>30 years	18	36%

Table 2: Categorisation of patients according to the diagnostic criteria in the uniform tuberculous meningitis research case definition.

Category	No.of patients	Percentage
Definitive TBM	4	8%
Probable TBM	31	62%
Possible TBM	12	24%
Not TBM	3	6%

According to the categories, M. TB was detected on GeneXpert as following

Table 3: No. of patients with MTB detected on Cbnaat.

Category	Total no.	Mtb detected	Mtb not detected
Definitive TBM	4	2(50%)	2(50%)
Probable TBM	31	10(32%)	21(68%)
Possible TBM	12	3(25%)	9(75%)
Not TBM	3	0	3

To calculate statistical values, Definitive, probable and possible TBM were grouped together. So, total study patients were divided into two groups: TBM and Not TBM. Total 15 patients had M. TB detected in their CSF on CBNAAT, out of a total of 47 TBM patients.

Table 3(a): No. of patients with MTB detected on CBNAAT.

Category	Total no	Mtb detected	Mtb not detected
TBM	47	15	32
Not TBM	3	0	3

Table 4: No. of patients with R- resistance on CBNAAT.

Category	Total no	MTB detected	MTB not detected	Rifampicin resistance detected
TBM	47	15	32	0
Not TBM	3	0	3	0

DISCUSSION

Tuberculosis (TB) is a global health concern. India is highest TB burden country in the world and accounts for one fourth of the global TB burden cases. In 2015, an estimated 28 lakh cases occurred and 4.8 lakh people died due to TB.13 Extrapulmonary Tuberculosis (EPTB) accounts for about 15 to 20% of all cases of Tuberculosis in India. The percentage may be higher in children and in HIV infected individuals. In HIV positive patients, EPTB accounts for more than 50 per cent of all cases of TB.14 Int. J. Curr. Res. Med. Sci. (2018). 4(2): 59-65 64 Exact prevalence of CNS TB in India is not known, but it accounts for an estimated 1% of all cases of TB, which equates to around 17 000 cases in India in2014 (WHO, 2015). Case fatality rates for the most common form of CNS TB, i.e. TB meningitis, are high15.A definitive diagnosis of mycobacterium infection depends on detection of the Mycobacterium Tuberculosis in CSF. It can be either done by smear microscopy which has very low sensitivity in CSF sample or by culture which has good sensitivity but takes too long to give the results. So, CBNAAT was proposed as a promising tool to detect M. TB early with increased sensitivity as compared to smear microscopy.

Sensitivity of CBNAAT in CSF has been variable among various studies. The pooled sensitivity of CBNAAT in CSF in a meta-analysis was 80.9%.16 Other studies showed sensitity ranging from 40%17 to 59.3%18. Its use for diagnosis of TBM has also been endorsed by INDEX TB guidelines. Thus, this study was planned to determine the sensitivity and utility of CBNAAT in diagnosis of TBM at a tertiary care centre in Punjab**.**

The sensitivity of CBNAAT in our study was 31% which is comparable with results of other studies. Also, resistance was detected in 1 patient. Thus, Gene Xpert MTB/RIF assay is an efficient and reliable technique for detection of M. TB in CSF samples. Its simplicity, speed and automation, and detection of resistance at the same time makes this technique a very attractive tool for the rapid diagnosis of TB meningitis, especially in suspected cases.

This findings suggest that CBNAAT important role in the diagnosis of tubercular meningitis, particularly in places with high burden and limited availability of resources. CBNAAT could be the best aid for physicians in diagnosing TBM if more awareness is brought among them regarding its utility. Our study highlighted that CBNAAT can be a faster alternative to time taking methods like culture DST and at the same time a more efficient alternative to other rapid methods like AFB smear examination in the diagnosis of TBM.

REFERENCES

1. Green PH. Tubercular meningitis. Lancet, 1836; 26: 232–5.
2. Sagarika Haldar, Neera Sharma,V. K. Gupta, Jaya Sivaswami Tyagi. Efficient diagnosis of tuberculous meningitis bydetection of Mycobacterium tuberculosis DNA incerebrospinal fluid filtrates using PCR.Journal of Medical Microbiology, 2009; 58: 616–624.
3. Thwaites GE, van Toorn R, Schoeman J. Tuberculous meningitis: More questions, still too few answers. Lancet Neurol, 2013; 12: 999– 1010.
4. Thwaites G, Chau TT, Mai NT, Drobniewski F, McAdam K, Farrar J. Tuberculous meningitis. J Neurol Neurosurg Psychiatry, 2000; 68: 289– 99.
5. http://www.stoptb.org/wg/gli/assets/documents/ WHO Policy Statement onXpert MTB-RIF, 2013. 22102013.pdf
6. Blakemore R, Story E, Helb D, Kop J, Banada P. Evaluation of the analytical performance of the Xpert MTB/RIF assay. J Clin Microbiol, 2010; 48: 2495–2501.
7. Helb D, Jones M, Story E, Boehme C, Wallace E. Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technology. J Clin Microbiol, 2010; 48: 229– 237.
8. Raja S, Ching J, Xi L, Hughes SJ, Chang R. Technology for automated, rapid, and quantitative PCR or reverse transcription-PCR clinical testing. Clin Chem, 2005; 51: 882–890.
9. American Thoracic Societ. Diagnostic standards and classification of tuberculosis in adults and children. Am J Respir Crit Care Med, 2000; 161: 1376–1395.
10. Hobby GL, Holman AP, Iseman MD, Jones JM Enumeration of tubercle bacilli in sputum of patients with pulmonary tuberculosis. Antimicrob Agents Chemother, 1973; 4: 94–104.
11. van Zyl-Smit RN, Binder A, Meldau R, Mishra H, Semple PL. Comparison of quantitative techniques including Xpert MTB/RIF to evaluate mycobacterial burden, 2011; 6 (12): 28815.
12. Marais S. Thwaites G., Schoeman JF.Tuberculous meningitis: a uniform case definition for use in clinical research.The Lancet Infectious Diseases, 2010; 10(11): 803 – 812.
13. Annual Status Report. Revised National Tuberculosis Control Program, Chapter 2, TB Disease Burden in India. TB India, 2017. Availablein:https://tbcindia.gov.in/WriteReadData/T B%20I ndia%202017.pdf
14. Raviglione MC, Narain JP, Kochi A. HIV-associated tuberculosis in developing countries: clinical features, diagnosis, and Int. J. Curr. Res.

Med. Sci, 2018; 4(2): 59-65. treatment. Bulletin of the World Health Organization.

15. Index TB guidelines,Central TB Division,Ministry of Health and Family Welfare, Government of India.

16. Denkinger CM, Schumacher SG, Boehme CC, Dendukuri N, Pai M, Steingart KR. Xpert MTB/RIF assay for the diagnosis of extrapulmonary tuberculosis: a systematic review and meta-analysis. European Respiratory Journal, 2014; 44(2): 435-46.

17. Srwar A, Akhtar R, Ahmad I, Mukhtar MN, Imran S, Akbar H, Ali S, Usman M. Rapid detection of Mycobacterium tuberculosis and Rifampicin Resistance in extra pulmonary samples using Gene Xpert MTB/RIF assay.

18. Nhu NT, Heemskerk D, Chau TT, Mai NT, Nghia HD, Loc PP, Ha DT, Merson L, Van Thinh TT, Day J, van Vinh Chau N. Evaluation of GeneXpert MTB/RIF for diagnosis of tuberculous meningitis. Journal of clinical microbiology, 2014; 52(1): 226-3.